UB Paderborn / Katalog / Suche / in CDI

1 – 25 von 217

Sortiert nach

The Selective Tie2 Inhibitor Rebastinib Blocks Recruitment and Function of Tie2Hi Macrophages in Breast Cancer and Pancreatic Neuroendocrine Tumors

Molecular cancer therapeutics, 2017-11, Vol.16 (11), p.2486-2501

2017

Link zum Volltext

Verfügbarkeit prüfen

Vimseltinib: A Precision CSF1R Therapy for Tenosynovial Giant Cell Tumors and Diseases Promoted by Macrophages

Molecular cancer therapeutics, 2021-11, Vol.20 (11), p.2098-2109

2021

Link zum Volltext

Verfügbarkeit prüfen

cJun overexpression in MCF-7 breast cancer cells produces a tumorigenic, invasive and hormone resistant phenotype

Oncogene, 1999-10, Vol.18 (44), p.6063-6070

1999

Link zum Volltext

Verfügbarkeit prüfen

Discovery of vimseltinib (DCC-3014), a highly selective CSF1R switch-control kinase inhibitor, in clinical development for the treatment of Tenosynovial Giant Cell Tumor (TGCT)

Bioorganic & medicinal chemistry letters, 2022-10, Vol.74, p.128928-128928, Article 128928

2022

Link zum Volltext

Verfügbarkeit prüfen

Discovery of acyl ureas as highly selective small molecule CSF1R kinase inhibitors

Bioorganic & medicinal chemistry letters, 2022-10, Vol.74, p.128929-128929, Article 128929

2022

Link zum Volltext

Verfügbarkeit prüfen

Abstract 3242: In depth myeloid cell characterization in the murine syngeneic CT26 colon carcinoma model by 10 color flow cytometry

Cancer research (Chicago, Ill.), 2016-07, Vol.76 (14_Supplement), p.3242-3242

2016

Link zum Volltext

Verfügbarkeit prüfen

Discovery of 1‑(3,3-Dimethylbutyl)-3-(2-fluoro-4-methyl-5-(7-methyl-2-(methylamino)pyrido[2,3‑d]pyrimidin-6-yl)phenyl)urea (LY3009120) as a Pan-RAF Inhibitor with Minimal Paradoxical Activation and Activity against BRAF or RAS Mutant Tumor Cells

Journal of medicinal chemistry, 2015-05, Vol.58 (10), p.4165-4179

2015

Link zum Volltext

Verfügbarkeit prüfen

Altiratinib Inhibits Tumor Growth, Invasion, Angiogenesis, and Microenvironment-Mediated Drug Resistance via Balanced Inhibition of MET, TIE2, and VEGFR2

Molecular cancer therapeutics, 2015-09, Vol.14 (9), p.2023-2034

2015

Link zum Volltext

Verfügbarkeit prüfen

The ABL switch control inhibitor DCC-2036 is active against the chronic myeloid leukemia mutant BCR-ABLT315I and exhibits a narrow resistance profile

Cancer research (Chicago, Ill.), 2011-05, Vol.71 (9), p.3189-3195

2011

Link zum Volltext

Verfügbarkeit prüfen

Phase 1 dose-finding study of rebastinib (DCC-2036) in patients with relapsed chronic myeloid leukemia and acute myeloid leukemia

Haematologica (Roma), 2017-03, Vol.102 (3), p.519-528

2017

Link zum Volltext

Verfügbarkeit prüfen

1455 Characterization of gene expression signatures of tumor immunogenicity and cellular proliferation from murine cancer models grown in vitro and in vivo

Journal for immunotherapy of cancer, 2023-11, Vol.11 (Suppl 1), p.A1618-A1618

2023

Link zum Volltext

Verfügbarkeit prüfen

Switch control pocket inhibitors of p38-MAP kinase. Durable type II inhibitors that do not require binding into the canonical ATP hinge region

Bioorganic & medicinal chemistry letters, 2010-10, Vol.20 (19), p.5793-5798

2010

Link zum Volltext

Verfügbarkeit prüfen

Abstract 5667: High-throughput analysis of MAPK and JAK-STAT signaling in CT26 tumors using a combination of immunophenotyping and phospho-flow cytometry

Cancer research (Chicago, Ill.), 2018-07, Vol.78 (13_Supplement), p.5667-5667

2018

Link zum Volltext

Verfügbarkeit prüfen

c-Jun Can Mediate Androgen Receptor-induced Transactivation

The Journal of biological chemistry, 1996-10, Vol.271 (40), p.24583-24589

1996

Link zum Volltext

Verfügbarkeit prüfen

Examination of edge effects with different storage conditions of preplated dimethyl sulfoxide nanospots in ChemLib 1,536- and 3,456-well assay-ready plates

Assay and drug development technologies, 2008-12, Vol.6 (6), p.811

2008

Link zum Volltext

Verfügbarkeit prüfen

Simultaneous screening of multiple bacterial tRNA synthetases using an Escherichia coli S30-based transcription and translation assay

Assay and drug development technologies, 2007-08, Vol.5 (4), p.515

2007

Link zum Volltext

Verfügbarkeit prüfen

Abstract 5624: Characterization of proliferation in multiple T-cell subsets in the CT26 murine colon carcinoma model by multi-color flow cytometry

Cancer research (Chicago, Ill.), 2017-07, Vol.77 (13_Supplement), p.5624-5624

2017

Link zum Volltext

Verfügbarkeit prüfen

Abstract 1668: Comprehensive 10 color flow cytometry analysis of the neuroblastoma intratumoral immune response using the murine syngeneic neuro-2a tumor model

Cancer research (Chicago, Ill.), 2017-07, Vol.77 (13_Supplement), p.1668-1668

2017

Link zum Volltext

Verfügbarkeit prüfen

Abstract 2690: DCC-2618 is a potent inhibitor of wild-type and mutant KIT, including refractory Exon 17 D816 KIT mutations, and exhibits efficacy in refractory GIST and AML xenograft models

Cancer research (Chicago, Ill.), 2015-08, Vol.75 (15_Supplement), p.2690-2690

2015

Link zum Volltext

Verfügbarkeit prüfen

Targeting the KIT activating switch control pocket: a novel mechanism to inhibit neoplastic mast cell proliferation and mast cell activation

Leukemia, 2013-02, Vol.27 (2), p.278-285

2013

Link zum Volltext

Verfügbarkeit prüfen

Abstract 790: Altiratinib is a potent inhibitor of TRK kinases and is efficacious in TRK-fusion driven cancer models

Cancer research (Chicago, Ill.), 2015-08, Vol.75 (15_Supplement), p.790-790

2015

Link zum Volltext

Verfügbarkeit prüfen

Identification of domains of c-Jun mediating androgen receptor transactivation

Oncogene, 1998-04, Vol.16 (15), p.2001-2009

1998

Link zum Volltext

Verfügbarkeit prüfen

Abstract A53: The specific FMS kinase inhibitor, DCC-3014, durably inhibits FMS kinase in vivo and blocks cancer bone invasiveness

Cancer research (Chicago, Ill.), 2015-01, Vol.75 (1_Supplement), p.A53-A53

2015

Link zum Volltext

Verfügbarkeit prüfen

1 – 25 von 217

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(204)
Mit Volltextzugriff
(202)

Publikationsform

Sprache

Englisch
(217)
Japanisch
(39)

Erscheinungsjahr

n.n

Thema

Science & Technology
(146)
Life Sciences & Biomedicine
(131)
Humans
(99)
Female
(71)
Male
(67)
Biological And Medical Sciences
(48)
Middle Aged
(42)
Medical Sciences
(36)
Animals
(33)
Adult
(30)
Aged
(30)
Fundamental And Applied Biological Sciences. Psychology
(18)
Physical Sciences
(18)
Respiratory System
(18)
Cell Biology
(16)
General & Internal Medicine
(16)
Surgery
(14)
Biochemistry & Molecular Biology
(13)
Forced Expiratory Volume
(13)
Oncology
(13)

15 weitere anzeigen...

Weniger anzeigen...

Neu hinzugefügt

... seit 90 Tagen
(4)

Menü

Weitere Dienste

Einstellungen

Ripretinib (DCC-2618) Is a Switch Control Kinase Inhibitor of a Broad Spectrum of Oncogenic and Drug-Resistant KIT and PDGFRA Variants

Conformational Control Inhibition of the BCR-ABL1 Tyrosine Kinase, Including the Gatekeeper T315I Mutant, by the Switch-Control Inhibitor DCC-2036

The Selective Tie2 Inhibitor Rebastinib Blocks Recruitment and Function of Tie2Hi Macrophages in Breast Cancer and Pancreatic Neuroendocrine Tumors

Vimseltinib: A Precision CSF1R Therapy for Tenosynovial Giant Cell Tumors and Diseases Promoted by Macrophages

cJun overexpression in MCF-7 breast cancer cells produces a tumorigenic, invasive and hormone resistant phenotype

Discovery of vimseltinib (DCC-3014), a highly selective CSF1R switch-control kinase inhibitor, in clinical development for the treatment of Tenosynovial Giant Cell Tumor (TGCT)

Discovery of acyl ureas as highly selective small molecule CSF1R kinase inhibitors

Abstract 3242: In depth myeloid cell characterization in the murine syngeneic CT26 colon carcinoma model by 10 color flow cytometry

Discovery of 1‑(3,3-Dimethylbutyl)-3-(2-fluoro-4-methyl-5-(7-methyl-2-(methylamino)pyrido[2,3‑d]pyrimidin-6-yl)phenyl)urea (LY3009120) as a Pan-RAF Inhibitor with Minimal Paradoxical Activation and Activity against BRAF or RAS Mutant Tumor Cells

Altiratinib Inhibits Tumor Growth, Invasion, Angiogenesis, and Microenvironment-Mediated Drug Resistance via Balanced Inhibition of MET, TIE2, and VEGFR2

The ABL switch control inhibitor DCC-2036 is active against the chronic myeloid leukemia mutant BCR-ABLT315I and exhibits a narrow resistance profile

Phase 1 dose-finding study of rebastinib (DCC-2036) in patients with relapsed chronic myeloid leukemia and acute myeloid leukemia

1455 Characterization of gene expression signatures of tumor immunogenicity and cellular proliferation from murine cancer models grown in vitro and in vivo

Switch control pocket inhibitors of p38-MAP kinase. Durable type II inhibitors that do not require binding into the canonical ATP hinge region

Abstract 5667: High-throughput analysis of MAPK and JAK-STAT signaling in CT26 tumors using a combination of immunophenotyping and phospho-flow cytometry

c-Jun Can Mediate Androgen Receptor-induced Transactivation

Examination of edge effects with different storage conditions of preplated dimethyl sulfoxide nanospots in ChemLib 1,536- and 3,456-well assay-ready plates

Simultaneous screening of multiple bacterial tRNA synthetases using an Escherichia coli S30-based transcription and translation assay

Abstract 5624: Characterization of proliferation in multiple T-cell subsets in the CT26 murine colon carcinoma model by multi-color flow cytometry

Abstract 1668: Comprehensive 10 color flow cytometry analysis of the neuroblastoma intratumoral immune response using the murine syngeneic neuro-2a tumor model

Abstract 2690: DCC-2618 is a potent inhibitor of wild-type and mutant KIT, including refractory Exon 17 D816 KIT mutations, and exhibits efficacy in refractory GIST and AML xenograft models

Targeting the KIT activating switch control pocket: a novel mechanism to inhibit neoplastic mast cell proliferation and mast cell activation

Abstract 790: Altiratinib is a potent inhibitor of TRK kinases and is efficacious in TRK-fusion driven cancer models

Identification of domains of c-Jun mediating androgen receptor transactivation

Abstract A53: The specific FMS kinase inhibitor, DCC-3014, durably inhibits FMS kinase in vivo and blocks cancer bone invasiveness

Suchergebnisse filtern